138 results about "Neuroblastoma" patented technology

The invention provides a child abdominal common solid tumor activity image evaluation method and device and a medium, and the method comprises the steps: capturing the change information of a focus on a vein phase image after plain scanning and enhancement through a 3D convolutional neural network model, carrying out the intelligent silhouette, and generating an enhancement region and the enhancement degree of the focus after chemotherapy, thereby achieving the evaluation of the activity of a child abdominal common solid tumor. And finally, integrating all the information to perform intelligent diagnosis, judging the tumor activity, and forming an artificial intelligence auxiliary activity evaluation scheme after chemotherapy of the abdominal solid tumor. According to the method, the automatic enhancement degree quantitative evaluation of the hepatoblastoma, the nephroblastoma and the neuroblastoma of the children is realized through automatic tumor segmentation and registration subtraction image calculation by utilizing the plain scanning and enhanced CT image, so that the focus characteristics are extracted from multiple angles, the image information is fully mined, and the accuracy of the diagnosis is improved. Accuracy and sensitivity of activity discrimination after chemotherapy of the solid abdominal tumor of children can be obviously improved.

The invention discloses a novel polypeptide, a polypeptide derivative and application thereof, and belongs to the technical field of biological medicine. The invention specifically relates to a specific sequence, a discovery process, a specific anti-tumor type, a long-acting modification mode and application of the novel polypeptide. The tumors comprise one or more of brain glioma, neuroblastoma, head and neck cancer, esophagus cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestinal cancer, ileocecum cancer, stomach cancer, bladder cancer, pancreatic cancer, prostate cancer, bile duct cancer, melanoma, sarcoma, myeloma, lymphoma and leukemia; the compound has the specific effect of inhibiting proliferation and / or metastasis of tumor cells, is wide in treatment spectrum and has important treatment value in various tumors.

The invention discloses a neuroblastoma pathological image classification method based on a CMSwinKAN neural network, and the method comprises the steps: firstly building a neuroblastoma pathological image data set, and dividing the data set into a training set and a test set; a CMSwinKAN neural network model is constructed, wherein the CMSwinKAN neural network model comprises a SwinKANsform feature extraction module, a comparison driving multi-scale aggregation module and a kernel activation network classification head; performing feature classification on the slices through an SVM classifier to obtain classification confidence; dynamically weighting the output of the CMSwinKAN neural network model according to the classification confidence, and outputting a final classification result; and taking the training set as input, training the CMSwinKAN model and the SVM classifier, and adjusting and optimizing parameters of the CMSwinKAN neural network model and the SVM classifier.

To provide therapeutic methods and compositions for the treatment of neuroblastoma in juvenile mammals.SOLUTION: A method for treating neuroblastoma comprises a step for administering a composition to a patient, where the composition is composed of at least one from the group consisting of: taurinamide; taurultam; methylene glycol; taurultam and taurinamide in a ratio of 1 taurultam: 7 taurinamide; and taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam: 7 taurinamide: 1 methylene glycol.SELECTED DRAWING: Figure 3

Disclosed are a novel polypeptide, a polypeptide derivative and the use thereof, which belong to the technical field of biomedicine. The present application specifically relates to a specific sequence, a discovery process, specific types of tumors to be resisted, a long-acting modification method and the use of the novel polypeptide, wherein the tumors include one or more of glioma, neuroblastoma, head and neck cancer, esophageal cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestine cancer, ileocecal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, cholangiocarcinoma, melanoma, sarcoma, myeloma, lymphoma and leukemia; and the specific use comprises the inhibition of the proliferation and / or metastasis of the above-mentioned tumor cells. The novel polypeptide has a wide therapeutic spectrum and important therapeutic value against various tumors.

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.

The present disclosure relates, inter alia, to the combination therapy of an oncolytic adenovirus for the treatment of retinoblastoma, Ewing's sarcoma or neuroblastoma with a topoisomerase I inhibitor or a prodrug thereof, such as topotecan or SN-38, or a prodrug of a topoisomerase inhibitor, such as irinotecan.

The invention discloses application of a prognostic marker H4K5la in prognostic evaluation of neuroblastoma, and relates to the technical field of biology. The invention provides application of the H4K5la detection reagent in preparation of products for judging prognosis of neuroblastoma, prognosis evaluation accuracy is improved by detecting the expression level of H4K5la, the detection cost is reduced by the detection method, detection sensitivity and specificity are enhanced, a theoretical basis is provided for a treatment intervention strategy of targeted H4K5la, and the application of the H4K5la detection reagent in preparation of products for judging prognosis of neuroblastoma is provided. Important reference can be provided for further treatment development.

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The present invention provides a GD2-targeting CAR-T cell and its preparation and application. Specifically, the present invention provides a GD2-targeting CAR construct, which comprises the scFv fragment of the humanized GD2 antibody 3F8, the human Fc fragment, the ICOS transmembrane region, the ICOS and 4-1BB intracellular regions (co-stimulatory signals), and CD3ζ. The present invention also provides a CAR-T cell based on the above CAR, its preparation method and application. The CAR-T cell of the present invention can significantly inhibit the proliferation of tumor cells in a subcutaneous model of neuroblastoma, has a significant in vivo anti-tumor effect, and can be used for the targeted treatment of neuroblastoma.

The invention belongs to the field of neuroblastoma tissue analysis, and particularly discloses a child neuroblastoma tissue microarray chip and a preparation method thereof.The child neuroblastoma tissue microarray chip comprises a glass slide base material, and a plurality of neuroblastoma tissue samples arranged in a dot-matrix mode are arranged on the glass slide base material; by integrating a plurality of neuroblastoma samples including various pathological typing, grading and clinical staging types of neuroblastoma in a tissue block, efficient sample processing and analysis are achieved, comprehensiveness and representativeness of research are ensured, a large number of samples are analyzed simultaneously through a microarray technology, and the accuracy and accuracy of analysis are improved. The requirements for high-throughput screening of specific genes and expression proteins thereof in scientific research activities are met, the prediction capacity for tumor prognosis and the guidance accuracy for treatment schemes are improved, and neuroblastoma tissues are analyzed more efficiently and comprehensively.

Methods, compositions, and systems for treating various cancers are disclosed. The disclosed compositions may include a poly peptide with affinity for a CD99 cell surface protein. Disclosed polypeptides may comprise a sequence selected from GYYMH, RINPYTGATTYNQIFKD, YYYGNNYNVYLDY, SASQGISNYLS, YTSTLHIS, and QQYSNLPWT, and may include mouse, human, or humanized peptide sequences. In many embodiments, the polypeptides may be immunoglobulins, for example IgG3 or IgG4. The disclosed polypeptides may be administered to a subject having a cancer cell with elevated expression of CD99. In some embodiments, the subject may be suffering from cancer, including diffuse intrinsic pontine glioma (DIPG). Ewing Sarcoma, acute myeloid leukemia (AML), ependymoma, or neuroblastoma. Treatment methods include administering the disclosed polypeptides to a subject that may also be treated with radiation. Disclosed herein are systems for treating one or more cancers. The systems may comprise a radiation source, for example a medical fractionated radiation source.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170

The invention relates to a tricyclic heterocyclic compound as well as a preparation method and medical application thereof. Specifically, the invention relates to a compound shown in a general formula (I), a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound as an MAT2A inhibitor. The compound and the pharmaceutical composition containing the compound can be used for treating and / or preventing diseases related to MAT2A activity, such as mesothelioma, neuroblastoma, rectal cancer, colon cancer, esophageal cancer and the like. Wherein the definition of each group in the general formula (I) is the same as that in the specification.

The present invention discloses a tumor-targeting typhoid toxin B subunit mimetic peptide and its application. The typhoid toxin B subunit mimetic peptide is selected from any one of the six polypeptides YQPB-1: COOH-Thr-Gly-Ser-Gly-Asn-Ala-Asn-Val-NH2. The application of the typhoid toxin B subunit mimetic peptide or its dimer and multimer described in the present invention in the preparation of diagnostic reagents or tumor therapeutic drugs targeting tumors. The present invention has developed a series of new mimetic peptides that simulate the typhoid toxin B subunit (PltB) secreted by Salmonella typhi. The YQPB-X series of mimetic peptides can specifically bind to tumor cells with high expression of gangliosides. In vivo optical imaging and results have confirmed that they have excellent imaging results for various tumors such as neuroblastoma, non-small cell lung cancer, melanoma, breast cancer and osteosarcoma.

This invention discloses a polycyclic pyrimidine compound and its uses. The invention provides a polycyclic pyrimidine compound of formula (I), its solvate, a pharmaceutically acceptable salt thereof, a solvate of its pharmaceutically acceptable salt, its tautomer, or its stereoisomer. The compound provided by this invention exhibits good degradation activity against CDK9 and good inhibitory activity against neuroblastoma.

The present invention provides methods and kits a) for preventing and / or treating neuroblastoma (e.g., high-risk neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patients whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and / or +316 of the ODC1 gene. The invention also provides, cancer treatment methods comprising the determination of the ODC1 genotype at the +263 and / or +316 positions, as a means to guide treatment selection, which includes, in some aspects the administration of pharmaceutically effective amounts of α-difluoromethylornithine (DFMO), either as a monotherapy or in combination with one or more other drugs. In addition, the present invention provides methods for preventing and / or treating patients that have been determined to have cancer stem cells, such as patients in cancer remission that are at risk for relapse.

The present invention relates to a combination therapy for treating metastasis of a GD2-positive cancer, such as relapsed or refractory neuroblastoma. In particular, the combination therapy comprises administration of stereotactic body radiotherapy (SBRT) at one or more metastatic sites in combination with administration of an anti-GD2 antibody or fragment thereof.

The MYC and NMYC transcription factors (TFs) play a key role in cell proliferation and are overexpressed in most cancer cells. However, in normal cells their overexpression triggers safeguard mechanisms promoting cell death and cellular senescence, which are bypassed in cancer cells. Here, the inventors reveal that in normal cells MYC binds to the Inositol 1,4,5-Trisphosphate Receptor type 1 (ITPR1) gene and upregulates its expression, triggering an ER-mitochondria calcium (Ca2+) transfer, which is involved in MYC-induced cell death and senescence. Supporting a tumor suppressive role of MYC / ITPR1 axis, ITPR1 expression is generally decreased in cancer and reactivation of this pathway induces cancer cell death. Nevertheless, some cancer cells, generally expressing high levels of MYCN and / or MYC, also express high level of ITPR1, which correlates with high expression of BCL2, encoding an inhibitor of ITPR1. Strikingly, in high-risk MYCN-amplified neuroblastoma, ITPR1 expression is controlled by NMYC and its level correlates with worse patient survival. In these cells, blocking the interaction between BCL2 and ITPR1, via an BCL2-BH4 domain inhibitor induces mitochondrial Ca2+ accumulation and cell death, and decreases tumor size. Thus, the present invention relates to a method for treating MYChigh cancer, and in particular NMYC--amplified neuroblastoma in a subject by administering an BCL2-BH4 domain inhibitor.

Described herein are endoxifen compositions and methods using endoxifen compositions for treating various cancers. The endoxifen compositions may be used to treat cancers such as skin cancers, gastrointestinal cancers, neuroblastoma, breast cancers, cervical cancers, or ovarian cancers. A method of treating various cancers may include administering endoxifen to a subject having skin cancer, gastrointestinal cancer, neuroblastoma, breast cancer, cervical cancer, or ovarian cancer.

The invention provides a guide RNA (Ribonucleic Acid), the guide RNA is targeted to SFPQ (Small Form-Factor Pluggable Quantitative), and the primer sequence of the guide RNA is as follows: SFPQ sgRNA-FWD: 5 '-CGTACAAACGTGCCATG-3'; and SFPQ sgRNA-REV: 5 '-CATGGCACGTTTGAGTACG-3', and SFPQ sgRNA-REV: 5 '- The invention further provides an adeno-associated virus targeting the SFPQ, and the adeno-associated virus contains the guide RNA. The invention also provides an application of the adeno-associated virus targeting SFPQ in preparation of a medicine for treating neuroblastoma. The adeno-associated virus targeting SFPQ provided by the invention not only can inhibit tumor growth, but also can provide a new strategy for NB treatment by promoting NB cell differentiation.

The disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, a method for preparation thereof as well as use thereof in the treatment and / or diagnosis of cancer such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer and / or rhabdoid cancer.

Therapeutic nanoparticles for use in the treatment of neuroblastoma and other cancers. Therapeutic nanoparticles comprising: at least one tumor drug; and taurolidine, thereby providing simultaneous delivery of the at least one tumor drug and taurolidine, thereby utilizing the synergistic effect of taurolidine on the at least one tumor drug.

There is provided an anti-GD2 CAR T cell composition, a method for making such a composition and its use in the treatment of diseases such as Neuroblastoma.

An epigenetic silencer factor (ESF) for use in the treatment of cancer, or a polynucleotide encoding the same, wherein the ESF comprises a transcription factor DNA-binding domain functionally linked to at least one epigenetic effector domain, the transcription factor is an oncogenic transcription factor or a cancer-related transcription factor, and the cancer is selected from the group consisting of glioma, glioblastoma, medulloblastoma, astrocytoma, neuroblastoma, epithelioma, meningioma, retinoblastoma, rhabdomyosarcoma, lung cancer, prostate cancer, breast cancer, liver cancer, pancreatic cancer (e.g., human pancreatic ductal adenocarcinoma), bladder cancer, oropharyngeal cancer, kidney cancer, colon cancer (e.g., colon adenocarcinoma), colorectal cancer (CRC), or metastases of any of the foregoing.

The present disclosure relates to anti-GD2 and / or famesyltransferase inhibitor compositions for use in methods for treating a cancer, for example, neuroblastoma. Also provided is a method of preventing neuroblastoma metastasis, comprising administering to a subject a therapeutically effective amount of an anti-GD2 immunotherapy and a farnesyltransferase inhibitor. Further provided are compositions comprising tipifarnib and / or dinutuximab and methods of use thereof.

Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and / or astrocytes) and / or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.

The present invention belongs to the technical field of medicinal chemistry, specifically relates to a compound capable of binding to a CRBN protein and a composition thereof, and also relates to a protein degradation agent based on a CRBN protein and the use thereof. Specifically disclosed is a compound capable of binding to a CRBN protein, wherein the compound is composed of two sub-structure units A and B, the two sub-structures A and B are connected by means of a chemical single bond between Y of the sub-structure A and one of C2 (carbon at position 2), C4 (carbon at position 4), C5 (carbon at position 5), C6 (carbon at position 6) and C7 (carbon at position 7) of the sub-structure B, and the compound is as shown in formula I. The compound can be used as a structural unit of an E3 ubiquitin ligase ligand in PROTAC technology, thereby providing more therapeutic means for cancers or diseases such as prostate cancer, breast cancer, non-small cell lung cancer, Alzheimer's disease, neuroblastoma, hepatocellular carcinoma, colorectal cancer, pancreatic cancer, malignant rhabdomyosarcoma, and oral squamous cell carcinoma.

The present invention provides a B7-H3 chimeric antigen receptor modified T cell and its application. Specifically, the present invention provides an antibody targeting B7-H3, and a chimeric antigen receptor and an engineered immune cell prepared using the antibody. The present invention also provides a preparation method and application of antibodies and immune cells. The engineered immune cells of the present invention can effectively control the growth of tumor cells such as gastric cancer, osteosarcoma, breast cancer, neuroblastoma, pancreatic cancer, colon cancer, etc., and no obvious toxic side effects occur in in vivo experiments. It has very good safety and is expected to become an effective immunotherapy for the treatment of various solid tumors.